治疗性靶向癌症中的无义突变。
Therapeutic targeting of nonsense mutations in cancer.
机构信息
Karolinska Institutet, Departement of Oncology-Pathology, Stockholm, Sweden.
出版信息
Ups J Med Sci. 2024 May 27;129. doi: 10.48101/ujms.v129.10719. eCollection 2024.
Mutations in the tumor suppressor gene occur with high prevalence in a wide range of human tumors. A significant fraction of these mutations (around 10%) are nonsense mutations, creating a premature termination codon (PTC) that leads to the expression of truncated inactive p53 protein. Induction of translational readthrough across a PTC in nonsense mutant allows the production of full-length protein and potentially restoration of normal p53 function. Aminoglycoside antibiotics and a number of novel compounds have been shown to induce full-length p53 in tumor cells carrying various nonsense mutations. Full-length p53 protein generated by translational readthrough retains the capacity to transactivate p53 target genes and trigger tumor cell death. These findings raise hopes for efficient therapy of nonsense mutant tumors in the future.
肿瘤抑制基因的突变在广泛的人类肿瘤中高频发生。这些突变中有相当一部分(约 10%)是无义突变,产生一个过早终止密码子(PTC),导致截短的无活性 p53 蛋白的表达。在无义突变中诱导翻译通读可产生全长蛋白,并有可能恢复正常的 p53 功能。氨基糖苷类抗生素和许多新型化合物已被证明可诱导携带各种无义突变的肿瘤细胞中全长 p53 的表达。通过翻译通读产生的全长 p53 蛋白保留了激活 p53 靶基因并触发肿瘤细胞死亡的能力。这些发现为未来有效治疗无义突变肿瘤带来了希望。